Abstract:The success of gene therapy depends largely on the efficacy of gene delivery vector systems that can deliver genes to target organs or cells selectively and efficiently with minimal toxicity. Here, we show that by using the HRE.ppET-1 regulatory element, we were able to restrict expression of the transgene of vascular endothelial growth factor (VEGF) to endothelial cells exclusively in hypoxic conditions. Eukaryotic expression vectors such as pEGFP-HRE.ppET-1, pcDNA3.1-VEGF+Pa, pcDNA3.1-ppET-1+ EGF+Pa, and pcDNA3.1-HRE.ppET-1+VEGF+Pa were constructed by using a series of nuclear molecule handling methods like PCR, enzyme digestion. The recombinant vectors were transfected into HUVEC cells and HL7702 cells by the lipofectin method. GFP expression was observed with a fluorescence microscope to validate the specificity of expression in endothelial cells under the regulation of HRE.ppET-1 element. Cobalt chloride (final concentration 100 μmol/L) was added to the medium to mimic hypoxia in vitro. After transfection of vectors, the expression of VEGF mRNA was detected by RT-PCR, and the expression of VEGF was detected by Western blotting and ELISA methods under normoxia and hypoxia, respectively. The cell proliferation rate was detected by the MTT test. The expression of GFP revealed that the exterior gene was transcripted effectively in endothelial cells regulated by the HRE.ppET-1 element, while the expression of GFP was very weak in nonendothelial cells. The results of RT-PCR, Western blotting and ELISA showed that VEGF gene expression in the pcDNA3.1-HRE.ppET-1+VEGF+Pa group and in the pcDNA3.1-ppET-1+VEGF+Pa group was higher in hypoxia than it was in normoxia (P<0.05). The MTT test showed that the proliferation rate of HUVEC transfected with HPVA under hypoxia exceeded that of the control group. We conclude that the HRE.ppET-1 element was expressed specifically in endothelial cells, and can increase the expression of VEGF in hypoxia and stimulate proliferation of endothelial cells. Taking advantage of these facts could greatly improve the efficiency of gene therapy. The vector would be valuable for various gene transfer studies targeting endothelial cells.

Development of a hypoxia-responsive vector for tumor-specific gene therapy

Construction and verification of a hypoxia-induced gene therapy vector targeting hepatocellular carcinoma

Exploitation of Hypoxia Regulatory Vectors for Gene Therapy of Renal Anemia

The Targeting Expression of the Vascular Endothelial Growth Factor Gene in Endothelial Cells Regulated by HRE.ppET-1

Development of Endothelial-Specific Single Inducible Lentiviral Vectors for Genetic Engineering of Endothelial Progenitor Cells

Hypoxia-responsive Elements Enhancing the Toxicity of HSVtk-mediated Gene-Directed Enzyme Prodrug Therapy in Lung Cancer Cells Induced by Hypoxia

Abstract 2051: Hypoxia-induced Triple Suicide Gene TK/CD/UPRT Expression Enhances Cytotoxicity to GCV and 5-FC and Radiosensitization in Human Colorectal Cancer Cells

Development of Chimeric Gene Promoters Responsive to Hypoxia and Ionizing Radiation

Construction and identification of hypoxia regulatory reporter vectors

Hypoxia-directed tumor targeting of CRISPR/Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles

A Novel Adenoviral Vector Which Mediates Hypoxia-Inducible Gene Expression Selectively in Neurons

Hypoxia/radiation dual-sensitive promoters enhance the toxicity of HSVtk-mediated gene-directed enzyme prodrug therapy in Lung Cancer Cells

Cloning of HRE/CMV Promoters and Determination of Hypoxia Regulatory Activities

Abstract# 3787: A novel hTERT promoter driven E1A therapeutic for ovarian cancer

Adeno-associated Viral Vector-Mediated Hypoxia-Regulated VEGF Gene Transfer Promotes Angiogenesis Following Focal Cerebral Ischemia in Mice

Construction of Tumor Necrosis Factor Α(tnf-Α) Expression Vector Driven by a Hypoxia/radiation Dual-Sensitive Promoter and Observation of Improved Efficacy of TNF-α Expression in A549 Cells Transfected with the Vector and Its Subcutaneous Xe

Construction and Identification of an Effective Hypoxia-Inducible Expression Vector

A Novel Htert Promoter-Driven E1a Therapeutic for Ovarian Cancer

[Hypoxia Augments the Killing Effect of Herpes Simplex Virus Thymidine Kinase Gene Expression Actuated by the Promoter of the Vascular Endothelial Growth Factor Gene on Human Hepatocellular Tumor Cells].

Retroviral Vector-Mediated Hypoxia-Regulated Neurotrophin-3 Gene Transfer Reduces Apoptosis Induced by Hypoxia in PC12 Cells

How to overcome (and exploit) tumor hypoxia for targeted gene therapy